Leerink Partners analyst Geoff Porges maintained a Buy rating on Sanofi (SNYNF – Research Report) on October 12. The company’s shares closed last Thursday at $100.50.
According to TipRanks.com, Porges is a 2-star analyst with an average return of 1.1% and a 45.2% success rate. Porges covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Vertex Pharmaceuticals, and Theravance Biopharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $119.00 average price target, implying a 22.9% upside from current levels. In a report issued on September 27, Bernstein also maintained a Buy rating on the stock with a EUR120.00 price target.
See today’s best-performing stocks on TipRanks >>
Sanofi’s market cap is currently $126.1B and has a P/E ratio of 16.30. The company has a Price to Book ratio of -86.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
Read More on SNYNF:
- Leerink Partners Believes Gossamer Bio (GOSS) Won’t Stop Here
- Quanterix (QTRX) Gets a Buy Rating from Leerink Partners
- Analyst Explains Why They Upgraded Their Rating on InflaRx (IFRX)
- Athenex (ATNX) Gets a Hold Rating from Leerink Partners
- Robert W. Baird Maintains a Buy Rating on Albireo Pharma (ALBO)
